Please assess the completion status of the following clinical trial:

Trial Title: Study of AKR-501 Tablets Taken Orally Once Daily for 28 Days in Patients With Chronic Idiopathic Thrombocytopenic Purpura (ITP)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Men and women ≥ 18 years of age.~2. Confirmed diagnosis of ITP according to American Society of Hematology (ASH) Guidelines ≥ 3 months prior to Day 1.~3. If ≥ 60 years old, must have had either a bone marrow biopsy consistent with ITP within past 3 years or a good response (platelet count \> 100,000/mm\^3) to a previous ITP treatment.~4. Are refractory or relapsed after at least one prior ITP therapy (patients who are refractory and failed to achieve a platelet count ≥ 50,000/mm\^3 despite steroids or ≥ 30,000/mm\^3 to other prior ITP therapies, such as splenectomy, danazol, or immunosuppressive drugs. For patients who are relapsed, the platelet counts must be below 50,000/mm\^3 if using steroids or 30,000/mm\^3 if not prescribed steroids.)~5. Patients receiving maintenance corticosteroids may be enrolled, as long as the corticosteroids have been administered at a stable dose (same milligram amount ± 10%) for ≥ 2 weeks prior to Screening Visit A and the investigator does not foresee the need to change the steroid dose during study participation. Patients should remain on this stable corticosteroid dose during study participation.~6. Patients receiving stable dosages of cyclosporine A, mycophenolate mofetil, azathioprine or danazol may also be enrolled. The dosages of all these medications must be stable for at least 3 months prior to AKR-501 administration.~7. Platelet count:~   * Patients not receiving steroids (no steroid treatment for \> 2 weeks prior to the Screening Visit A): platelets \< 30,000/mm\^3 at Screening Visit A and within 96 hours prior to Day 1 (Screening Visit B)~  * Patients receiving steroids: platelets \< 50,000/mm\^3 at Screening Visit A and within 96 hours prior to Day 1 (Screening Visit B).~8. Women of child-bearing potential must have a negative pregnancy test at Screening Visit A and Screening Visit B. (Childbearing potential is defined as any woman who has not been surgically sterilized and is premenopausal or peri-menopausal i.e., any menstrual flow within 12 months of Screening Visit A).~9. Women of child-bearing potential and all men must agree to practice a medically approved form of contraception (one of the following must be used: condoms (male or female) with a spermicidal agent, diaphragm, or cervical cap with a spermicidal agent, IUD, hormonal contraception, abstinence).~10. Willing and able to provide written informed consent before any study-related procedure.~Exclusion Criteria:~1. Women who are pregnant and/or lactating.~2. Splenectomy procedure performed 4 weeks prior to AKR-501 administration.~3. Use of the following drugs or treatments prior to Day 1:~   * Within 3 months - Rituximab;~  * Within 2 weeks - Aspirin or Aspirin-containing compounds, Salicylates, Anticoagulants, clopidogrel, ticlopidine, Rh0(D) Immune Globulin (WinRho®), or intravenous immunoglobulin (IVIG).~4. Participation in a clinical trial involving any investigational agent within 4 weeks of Day 1.~5. Exposure to eltrombopag or AMG -531.~6. Significant medical conditions or diseases as determined by the Investigator (e.g., clinically active systemic lupus erythematosus; known or suspected HIV infection; acute hepatitis or clinically active chronic hepatitis; lymphoproliferative disease; congestive heart failure).~7. History of cardiovascular disease (e.g., angina, unstable angina, myocardial infraction, coronary artery stent placement, angioplasty, coronary artery bypass grafting).~8. History of thromboembolic disease (e.g., transient ischemic attack \[TIA\], stroke \[CVA\], pulmonary embolism \[PE\]).~9. History of deep venous thrombosis (DVT).~10. History of lupus anticoagulant or anticardiolipin antibody syndrome or positive anti b2 glycoprotein antibody.~11. History of any medical condition where systemic anticoagulation was required for more than 6 months.~12. Laboratory abnormalities:~    * Hemoglobin \< 12.5 g/dL for men and \< 11.5 g/dL for women. If anemia is clearly related to ITP, for example excessive blood loss, then that patient may be enrolled without the need for a waiver after discussion with the Sponsor's medical monitor~   * White blood cell count (WBC) \< lower limit of normal~   * Absolute neutrophil count (ANC) \< 1000/mm\^3~   * Prothrombin time (PT) \> 1.25 x upper limit of normal~   * Partial thromboplastin time (PTT) \> 1.25 x upper limit of normal~   * Total bilirubin \> 3 x upper normal limit~   * Alanine transaminase (ALT) \> 3 x upper normal limit~   * Aspartate transaminase (AST) \> 3 x upper normal limit~   * Creatinine \> 1.5x upper normal limit~   * Blood urea nitrogen (BUN) \> 1.5 x upper normal limit~   * HIV positive~   * IgM HAV positive, Hepatitis B surface antigen (HBsAg) or hepatitis C antibody (HCV) positive.~13. History of, or current alcohol or drug abuse likely to interfere with ability to comply with protocol.~    requirements or give informed consent, as determined by the Investigator.~14. History of, or current psychiatric illness likely to interfere with ability to comply with protocol requirements or give informed consent, as determined by the Investigator.~15. Currently taking any of the following medications: Rituximab, Aspirin or Aspirin-containing compounds, Salicylates, Anticoagulants, clopidogrel, ticlopidine, Rh0(D) Immune Globulin (WinRho®), or intravenous immunoglobulin (IVIG).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Avatrombopag tablets (Type: EXPERIMENTAL): 2.5, 5, 10 or 20 mg tablets~1 tablet taken orally once daily for 28 days
- Placebo tablet (Type: PLACEBO_COMPARATOR): 2.5, 5, 10, or 20 mg tablets~1 tablet taken orally once daily for 28 days

Based on this trial design, predict the completion outcome and termination type (if applicable).